Multiple Sclerosis Related Headaches

Thesis
Submitted in partial fulfillment
Of Master Degree in Neuropsychiatry

By
Aml Sayed Ashour Ali
M.B., B.Ch. (Cairo University)

Supervised by **Prof. Dr. Sherif H. Abd El-Maksoud**

Professor of Neurology Faculty of Medicine Cairo University

Prof. Dr. Hanan Amer

Assistant Professor of Neurology Faculty of Medicine Cairo University

Dr. Gihan Ramzy

Lecturer of Neurology Faculty of Medicine Cairo University

Faculty of Medicine Cairo University 2008



ACKNOWLEDGEMENT

First, and foremost, all thanks and gratitude to **GOD**, most gracious and most merciful.

I would like to express my deepest gratitude and sincere thanks to *Prof. Dr.*Sherif Hamdy, Professor of Neurology, Faculty of Medicine, Cairo University for his continuous guidance and valuable advice for enriching this work. I appreciate his hard support to me, which has given a powerful push helping this research to come to reality.

I am extremely grateful to *Dr. Hanan Amer*, Assistant Professor of Neurology, Cairo University for her continuous guidance and valuable suggestions, saving no effort or time to read every word in this work.

I would like to express my highest appreciation to *Dr. Gihan Ramzy*, Lecture of Neurology, Cairo University for her valuable help to inspire and implement this work, without which, it wouldn't have been a reality.

I would like to express my deep thanks and gratitude to *Dr. Amany Mahmoud*, Assistant Professor of Neurology, Cairo University for her continuous guidance and valuable suggestions in this work.

I would like to thank all my colleagues in the neurological department for their help and support.

My deepest gratitude to my *family* for their support and encouragement.

Abstract

Multiple sclerosis is a chronic disease that begins most commonly in young adults .MS lesions can occur in many different parts of the CNS, so they can cause a wide variety of symptoms and signs. Headache is a wide spread problem representing one of the ten most common symptoms in general medical practices Headache is considered as a one of pain syndromes associated with multiple sclerosis. The aim of this work was to study the association between MS and headache and to evaluate the correlation between headache (in general and its different types), the clinical features of MS and MRI lesion. This study conducted on 93 patients with definite MS. Patients were evaluated clinically using rating scales: EDSS, FSS, BDI, and headache intenisty scale. We found that the headache is a common symptom in MS patients, Migraine headache may represent as an MS attack. The presence of MS plaques in the infratentorial region is associated with an increase in the headache occurrence with migraine characteristic.

(Key words: Multiple sclerosis and headache)

LIST OF ABBREVIATIONS

Ach Acetyl choline

ADC Apparent diffusion coefficient

ADEM Acute demyelinating encephalomyelitis

AI Ambulation index

APP Avian pancreatic polypeptide

ATP Adenosine-5- triphosphate

BBB Blood-brain barrier

BDI Beck depression inventory

BDNF Brain derived neurotrophic factor.

CAMBS Cambridge multiple sclerosis basic score

CCR2 Chemokine receptor 2

CCR5 Chemokine receptor 5

CD MS Clinically definite MS

CFIDS Chronic Fatigue Immune Dysfunction Syndrome

CGRP Calcitonin gene related peptide

Cho Choline

CIS Clinically isolated syndromes

CNS Central nervous system

CNTF Ciliary neurotrophic factor

Cr Creatin

CSD Cortical spreading depression

CSE Conventional spin echo

CSF Cerebrospinal fluid

CTTH Chronic type headache

DA Dopamine

DRN Dorsal raphi nucleus

DT Diffusion tensor

DW Diffusion weighted imaging

EDRF Endothelial derived relaxing factors

EDSS Expanded disability scale

EJV External jugular vein

ES2 Exteroceptive suppression 2

ETTH Episodic type headache

FA Fractional anisotrophy

Fas L Fas ligand

FHM Familial hemiplegic migraine

FIM Functional Independence Measure

FLAIR Fluid attenuated inversional recovery

FMRI Functional magnetic resonance imaging

FSS Fatigue severity scale

GA Glatiramer acetate

GABA Gama-amino butyric acid

Gd Gadolinium

⁶⁸Gd-EDTA Gadolinium Ethylenediamineteraacetic acid

GNDS Guy Neurological Disability Scale

HDRS Hamilton Depression Rating Scale

HLA human leukocytic antigen

5HT 5-hydroxy tryptamine

ICAM-1 Intracellular adhesion molecule-1

ICH-II International headache society for headache classification

IFNb Interferon-beta

IgA, Immunoglobulin A

IgD Immunoglobulin D

IgG Immunoglobulin G

IgG index Immunoglobulin G index

IgM Immunoglobulin M

IL Interleukin

LC Locus ceruleus

LSD MS Laboratory-supported definite MS

MAG Myelin glycoprotein,

MBP Myelin basic protein

MD Mean diffusivity

MELAS Mitochondrial encephalopathy, lactic acidosis, and strokes

MHC Major histo- compitability complex

MHC Major histocompitability

mm millimeters

MMP-9 Matrix metalloproteinase 9

MOG Myelin oligodendrocyte glycoprotein

MRS Magnetic resonance spectroscopy

MS Multiple Sclerosis

MSFC MS Functional Composite

MT Magnetization transfer

MTR Magnetization transfer ratio

NA Noradrenaline

NAA N-acetyl aspartate

NAWM Normal appearing white matter

NDPH New daily-persistent headache

NK Natural killer cells

NKA Neurokinin A

NK_{IR} Neurokinin IR

NMDA N-methyl-D-aspartate

NMO Neuromyelitis optica

NO Nitric oxide

NOGO Neurite outgrowth inhibitor

NPY Neuropeotide Y

NSAIDs Non steroidal anti-inflammatory drugs

NSE Neural-specific enolase

OCBs Oligoclonal bands

PAG periaqueductal gray matter

PASAT Paced serial Addition Test

PD proton density

PET Positron emission tomography

PPMS Primary-Progressive MS

PRMS Progressive-Relapsing MS

rCBF regional cerebral blood flow

RR-MS relapsing remitting MS

SLE Systemic Lupus Erythromatosis

SNRS Scripps Neurological Rating Scale

SP Substance P

SPECT Single Photon Emission Computerized Tomography

SPMS Secondary-Progressive MS

SSEPs Somatosensory-evoked potentials

SUNCT Short-lasting unilateral neuralgiform headache attacks

with conjunctival injection and tearing

TAC's Trigeminal autonomic cephalgia's

^{99m}Tc-HMPAO Technectium 99m Hexa Methyl Propylene

Amine Oxime)

TE Echo time

TH T-helper

TN Trigeminal neuralgia

TNFR Tumor necrosis factor receptor

TPMS Transitional progressive MS

TR Repetition time

TTH Tension-type headache

VCAM-1 Vascular-cellular adhesion molecule-1

VIP Vasoactive intestinal peptide

VLA-4 Very late antigen-4

VEP Visual-evoked potential

List of Tables

Table (1): Pain syndromes associated with MS	8
Table (2): Comparison of MRI criteria for diagnosis	
of multiple sclerosis	22
Table (3): Benign multiple sclerosis features	36
Table (4): Prognostic indicators in multiple sclerosis	37
Table (5): Clinically isolated syndromes	39
Table (6): Diagnostic Laboratory tests for Multiple Sclerosis	42
Table (7): histopathological patterns in MS	59
Table (8): Summary of the mechanisms causing	
progressive pathology in MS	74
Table (9): Potential role of biomarkers in pathogenesis of MS	80
Table (10): The patient groups	154
Table (11): Age of patients of the total number of patients	
and patients in the group I & II	155
Table (12): Sex distribution of total number of patients	
and patients in the group I & II	155
Table (13): The duration of illness of the total number of patients	
and patients in the group I & II	157
Table (14): Course of multiple sclerosis among all patients	
and patients in the group I & II	157
Table (15): Age of MS onset of the total number of patients	
and patients in group the I & II	159
Table (16): The number of MS attacks of total number of	
patients and patients in the groups I &II.	159
Table (17): Primary headaches versus newly developed headaches	160
Table (18): Primary headache patients	161
Table (19): Newly developed headaches	
(secondary headaches)	161
Table (20): Comparison study between Primary headaches and	
newly developed headaches (secondary headache).	162
Table (21): Comparison study between group Ia and group Ib	164
Table (22): The site of MS related headache	165
Table (23): The frequency of headache attacks in the group Ia&Ib	165
Table(24): The duration of headache attack in the group Ia &Ib	166

Table (25a): headache severity scale (HSS) scores among	
patients of group Ia & Ib.	167
Table (25b): The frequency of HSS scores among patients of	
the group Ia &Ib	167
Table (26): HSS in primary and secondary headache patients	167
Table (27): EDSS scores of the total number of patients and	
of patients in the group I and II	168
Table (28):Comparison study of EDSS scores in the groups	
(Ia, Ib, II).	170
Table (29): EDSS scores in primary and secondary headache patient	ts 170
Table (30): The frequency of functional system affection in the total	
number of patients and in the group I&II	171
Table (31): Comparison study of functional systems affected in	
the groups Ia,Ib,II	172
Table (32): FSS scores of total number of patients and patients	454
in the group I&II	174
Table (33): Comparison study of FSS scores in the groups Ia,Ib,II	175
Table (34): FSS scores in primary and secondary headache patients	176
Table (35): Comparison study of BDI scores in the group I&II	177
Table (36): Comparison study of BDI scores in the groups Ia,Ib,II.	178
Table (37): BDI scores in the primary and secondary headache	170
patients	179
Table (38): Comparison study of lesion location in MRI in the	101
group I & II	181
Table (39a): Comparison study of the affection of the Midbrain in	100
the groups Ia, Ib, II. Table (20b): Comparison study of the affection of the comballum	182
Table (39b): Comparison study of the affection of the cerebellum	100
in the groups Ia,Ib,II. Table (20a): Comparison study of the affection of the temporal	182
Table (39c): Comparison study of the affection of the temporal	100
lobe in the groups Ia,Ib,II Table (40): Comparison study of lesion location in MRI in the	182
groups Ia,Ib,II	183
Table (41): Number of regions affected by MS plaques in	103
MRI of patients in groups I & II	184
Wiki of patients in groups I & II	104
Table (42): Comparison study of number of lesion locations in the	
brain MRI of patients in the groups Ia,Ib,II.	185
Table (43): Comparison study of number of lesion locations in the	- 30
brain and spine MRI of patients in the groups Ia.Ib.II	185

List of Tables

Table (44): Number of MS plaques in MRI of patients in the	
group I & II	186
Table (45a): Number of MS plaques in the brain MRI of patients	
in the the groups Ia,Ib,II.	186
Table (45b): Number of MS plaques in the brain & spine MRI	
of patients in the the groups Ia,Ib,II.	187

List of figures

Figure (1): Relatively specific sign of MS. Plaques through corpus		
callosum, arranged at right angles along venules	Dawnson	
finger	21	
Figure (2): RR MS with partial recovery	33	
Figure (3): RR MS with complete recovery	33	
Figure (4): PP MS without Plateaus	33	
Figure (5): PP MS with temporary minor improvements	33	
Figure (6): Secondary progressive (SP)	34	
Figure (7) Progressive-relapsing (PR) MS	35	
Figure (8): the role of immune system in MS pathogansis	68	
Figure (9): the impact of cytokines on oligodendrocytes		
and demyelination in MS	69	
Figure (10) Sex distribution in total number of patients	156	
Figure (11) Sex distribution in both group I&II	156	
Figure (12) Course of MS among all patients	157	
Figure (13) Course of MS in both group I&II	157	
Figure (14) HSS scores of patients in the group Ia & Ib	167	
Figure (15): EDSS scores among all patients	169	
Figure (16): Percentage of EDSS scores in the group I & II	169	

List of figures

Figure (17): Percentage of EDSS scores in the groups (Ia, Ib, II)	170
Figure (18): The functional system affection in the groups Ia,Ib,II	173
Figure (19) FSS scores among all patients	174
Figure (20) FSS scores in the groups I and II	174
Figure (21) FSS scores of patients in the groups Ia,Ib,II	175
Figure (22) BDI scores among all patients	177
Figure (23) BDI scores of the total number of patients and	
in the group I &II	177
Figure (24) BDI scores of patients in the groups Ia,Ib,II	178
Figure (25): MRI of the case (A)	263
Figure (26): MRI of the case (B)	264
Figure (27): MRI of the case (C)	265
Figure (28): MRI of the case (D)	266